

Ref: EPL/CS/SE/0020/2026

Date: March 09, 2026

To,

<b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	<b>BSE Limited</b> P J Towers, Dalal Street, Mumbai- 400 001
<b>Script Symbol: EMCURE</b>	<b>Scrip Code/Symbol: 544210/ EMCURE</b>

Dear Sir/Madam,

**Subject: Outcome of Board Meeting held on March 09, 2026.**

We wish to inform you that pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), read with Schedule III of aforesaid Regulation and SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, the Board of Directors of the Company at its meeting held today i.e. Monday, March 09, 2026, has *inter-alia* transacted and approved/ recommended the following businesses:

**1. Appointment of Mr. C S Muralidharan (DIN: 00014740) as an Additional Director (Non-Executive and Independent) and as an Independent Director of the Company:**

Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Mr. C S Muralidharan (DIN: 00014740) as an Additional Director (Non-Executive and Independent) with effect from April 01, 2026 and as an Independent Director for first term of three (3) consecutive years, with effect from April 01, 2026, subject to approval of Members of the Company.

Mr. C S Muralidharan is not debarred from holding the office of a Director by virtue of any Securities and Exchange Board of India ('SEBI') order and in accordance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018, or any such other authority, and he is not related to any Director(s) or Key Managerial Personnel(s) of the Company.

The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are provided in **Annexure A**, enclosed herewith.

## Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251

## 2. Approval for conducting Postal Ballot through remote e-voting and fixing of Cut-off Date and e-voting period:

Pursuant to Regulation 30 of the SEBI Listing Regulations, Postal Ballot through remote e-voting will be conducted and notice of the same shall be sent to the Members whose name is recorded in the Register of Members or in the Register of Beneficial Owners for seeking approval for appointment of an Independent Director as mentioned in Point 1. The Notice of the Postal Ballot, including other related information as required will be published and communicated in due course.

The meeting of the Board of Directors of the Company commenced at 12.15 p.m. (IST) and concluded at 12: 40 p.m. (IST).

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

**Amruta Yangalwar**  
**Company Secretary & Compliance Officer**  
**Membership Number: A25687**

*Encl: As above*

**Annexure- A**

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

<b>Sr. No.</b>	<b>Particulars</b>	<b>Information</b>
1	Name of the Director	Mr. C S Muralidharan
2	Reason for change viz. appointment, <del>re-appointment, resignation, removal, death or otherwise</del>	Appointment as an Additional Director (Non-Executive and Independent) with effect from April 01, 2026 and as an Independent Director of the Company with effect from April 01, 2026.
3	Date of appointment/ <del>re-appointment/</del> cessation (as applicable) & term of appointment/ <del>re-appointment</del>	Appointment as an Additional Director (Non-Executive and Independent) with effect from April 01, 2026 and as an Independent Director for first term of three (3) consecutive years, with effect from April 01, 2026, subject to approval of Members of the Company.
4	Brief profile (in case of appointment);	<p>Mr. C. S. Muralidharan has overall 40 years of corporate experience spread across hydro-carbon and pharmaceutical sectors. He has held various board and senior leadership positions across multiple entities in India, Asia and Europe. He has had proactive engagements with the Board demonstrating strong partnership on Strategy M&amp;A transactions, enterprise risk management, capital restructuring, enterprise transformation and ESG initiatives. He has previously worked with organizations like Indian Oil Corporation Limited, Ranbaxy Group, Lupin Limited, Matrix Laboratories Limited, Watson Group and in his last role, was associated with Sun Pharmaceutical Industries Limited, as Group Chief Financial Officer, where he was responsible for global finance, strategy, M&amp;A, investor relations, governance and compliance.</p> <p>Mr. Muralidharan is a Cost &amp; Management Accountant with a Master's degree in Commerce and has completed the Executive Program in General Management from Booth School of Business, University of Chicago.</p>
5	Disclosure of relationships between Directors (in case of appointment of a director).	Mr. Muralidharan is not related to any Director of the Company.

**Emcure Pharmaceuticals Limited**

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251